+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drug Eluting Balloon Market - Global Forecast 2026-2032- Product Image
Drug Eluting Balloon Market - Global Forecast 2026-2032- Product Image
Sale

Drug Eluting Balloon Market - Global Forecast 2026-2032

  • Report

  • 186 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4896654
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drug Eluting Balloon Market is projected to reach USD 1.48 Billion in 2026. It is expected to continue growing at a CAGR of 16.26%, reaching USD 3.66 Billion by 2032.

Drug eluting balloons, also known as drug-coated balloons, are catheter-based angioplasty devices that deliver an antiproliferative drug to the vessel wall without leaving a permanent implant. The technology is most established in peripheral artery disease, especially femoropopliteal lesions, and in selected coronary applications such as in-stent restenosis and small-vessel disease where avoiding additional metal layers can be clinically valuable.

The market is shaped by a strong evidence requirement because drug eluting balloon performance depends on drug choice, dose density, excipient chemistry, balloon transfer efficiency, lesion preparation, and operator technique. Randomized clinical studies, meta-analyses, and real-world registries have shown that effective drug-coated balloon platforms can reduce restenosis-related repeat procedures compared with plain balloon angioplasty in appropriate lesions, making the category strategically important for hospitals, ambulatory vascular centers, payers, and medical device manufacturers.

Transformative Shifts in the Drug Eluting Balloon Landscape

The drug eluting balloon landscape is moving from a single-product innovation story toward a broader vascular therapy platform. Paclitaxel-coated balloons built the commercial foundation because paclitaxel is lipophilic and transfers rapidly during short balloon inflation; however, manufacturers are now investing in sirolimus-coated balloon technologies to address safety perception, drug-release control, and use in more complex vascular beds.

Regulatory expectations have also transformed. The U.S. FDA updated its position in 2023, stating that available data did not support an excess late mortality risk for paclitaxel-coated devices, following years of additional follow-up and patient-level analyses. At the same time, Europe’s Medical Device Regulation has increased clinical evidence, technical documentation, and post-market surveillance obligations, pushing companies to build stronger trial, registry, and pharmacovigilance systems.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across the drug eluting balloon value chain rather than a standalone device feature. In clinical practice, AI-assisted angiographic and intravascular imaging analytics can support lesion measurement, calcification assessment, vessel sizing, dissections, recoil, and post-angioplasty result evaluation, all of which influence drug transfer and long-term patency.

For manufacturers, AI can improve coating process control, defect detection, batch consistency, sterilization validation review, and signal detection in post-market data. For health systems and payers, machine learning models can combine claims, imaging, comorbidity, and procedural data to identify patients at higher risk of restenosis or reintervention, supporting evidence-based device selection while preserving clinician oversight and regulatory compliance.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is a high-priority growth region because China, India, Japan, South Korea, and Australia face rising burdens of diabetes, aging-related vascular disease, and endovascular procedure demand. Japan and Australia have mature reimbursement pathways, experienced interventional specialists, and high-quality clinical governance, while China and India are expanding domestic manufacturing, hospital access, vascular training, and clinical adoption across large urban centers.

North America remains an evidence-driven market led by the United States, where FDA-approved drug-coated balloon indications, outpatient endovascular programs, and value-based care scrutiny shape purchasing decisions. Canada follows a more centralized health technology assessment and provincial reimbursement pathway, favoring devices with strong clinical, safety, and economic evidence.

Europe continues to be a major innovation and clinical evidence hub, but the EU Medical Device Regulation has increased documentation, clinical evaluation, notified body review, and post-market performance requirements. Latin America is led by Brazil and Mexico, where private hospitals adopt advanced endovascular devices faster than public systems, while reimbursement variability affects broader access. The Middle East, especially GCC healthcare systems, is investing in cardiovascular infrastructure and diabetes-related vascular care, while Africa remains constrained by uneven catheterization laboratory capacity, specialist availability, reimbursement gaps, and affordability.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are becoming more relevant as Thailand, Malaysia, Singapore, Indonesia, Vietnam, and the Philippines expand cardiovascular and peripheral vascular intervention services. Adoption is strongest where tertiary hospitals, private insurance, and specialist training support complex endovascular care, while price sensitivity and public procurement constraints continue to influence access.

The GCC benefits from national healthcare investment, high diabetes prevalence, and expansion of vascular centers, making evidence-based premium devices attractive when supported by procurement value analysis and clinician training. The European Union remains highly regulated under MDR, favoring suppliers with rigorous clinical evidence, UDI readiness, quality management discipline, and post-market surveillance systems.

BRICS countries represent large-volume opportunity but require localized pricing, registration expertise, domestic partnership strategies, and physician education. The G7 markets are characterized by advanced intervention capacity, mature payer systems, strong clinical trial ecosystems, and stricter evidence standards. NATO-aligned markets overlap significantly with North America and Europe, where supply chain resilience, regulatory compliance, cybersecurity, traceability, and trusted manufacturing networks are increasingly important for medical device procurement.

Key Country Insights Across Major Drug Eluting Balloon Markets

The United States is the largest strategic market due to FDA-cleared and FDA-approved device pathways, robust specialist adoption, extensive clinical trial activity, and strong outpatient vascular intervention activity. Canada emphasizes clinical evidence and provincial budget impact, while Mexico’s adoption is concentrated in private hospitals and major public referral centers. Brazil is Latin America’s most important country market because of its population scale, established interventional cardiology base, growing endovascular capability, and concentration of advanced care in major metropolitan regions.

In Europe, the United Kingdom prioritizes National Health Service value, clinical guidance, and procurement efficiency. Germany benefits from a large hospital base and advanced cardiovascular intervention capacity, while France, Italy, and Spain combine specialist expertise with reimbursement pressure and stronger demand for real-world evidence. Russia remains a complex market shaped by localization, procurement policy, registration requirements, and geopolitical constraints.

China is scaling domestic innovation, hospital adoption, and regulatory modernization, India is driven by vascular disease burden, diabetes prevalence, affordability needs, and expanding private healthcare capacity, and Japan is characterized by high-quality evidence expectations, advanced physician training, and disciplined reimbursement review. Australia has a mature specialist environment and structured reimbursement evaluation, while South Korea combines strong hospital technology adoption, physician expertise, and an export-oriented medical device ecosystem.

Actionable Recommendations for Drug Eluting Balloon Industry Leaders

Industry leaders should prioritize differentiated clinical evidence, not only product availability. Trials and registries should focus on lesion-specific outcomes, durability, freedom from target lesion revascularization, limb outcomes, wound healing, patient-reported measures, and real-world performance in diabetes, chronic kidney disease, long lesions, calcified disease, below-the-knee disease, and in-stent restenosis.

Manufacturers should invest in AI-enabled quality systems, coating consistency analytics, digital physician training, and post-market surveillance. Commercial teams should align claims with approved indications, build health economic dossiers for payers, strengthen adverse-event reporting, and localize strategies for MDR-regulated Europe, FDA-driven North America, fast-growing Asia-Pacific, and price-sensitive emerging markets.

Research Methodology

This executive summary is based on structured secondary research and evidence triangulation across regulatory communications, clinical trial publications, peer-reviewed vascular and interventional cardiology literature, medical society guidance, reimbursement context, public regulatory filings, and public health data related to peripheral artery disease, coronary restenosis, diabetes, chronic kidney disease, and endovascular procedures.

The methodology emphasizes verified and reproducible sources, including FDA safety communications, European regulatory requirements, published randomized studies, meta-analyses, post-market registries, and country-level healthcare infrastructure indicators. Insights are synthesized to identify market direction, clinical relevance, regional adoption patterns, technology shifts, and strategic implications for drug eluting balloon stakeholders while avoiding unsupported sizing, share, or forecasting assumptions.

Conclusion

Drug eluting balloons are positioned at the intersection of minimally invasive vascular therapy, device-based drug delivery, and evidence-driven healthcare purchasing. Their central value proposition is the ability to inhibit restenosis while avoiding permanent implants, which remains relevant in peripheral and selected coronary interventions.

Future market leadership will depend on proven outcomes, disciplined regulatory execution, coating and drug-delivery innovation, physician education, and real-world evidence generation. Companies that combine clinical credibility with scalable manufacturing, digital surveillance, compliant market access, and localized adoption strategies are best positioned to compete as the drug eluting balloon market evolves.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Drug Eluting Balloon Market, by Drug Type
7.1. Introduction
7.2. Paclitaxel-Coated
7.3. Sirolimus-Coated
8. Drug Eluting Balloon Market, by Product Type
8.1. Introduction
8.2. Conventional Balloon
8.3. Specialty Balloon
9. Drug Eluting Balloon Market, by Application
9.1. Introduction
9.2. Coronary Artery Disease
9.2.1. De Novo Lesion
9.2.2. In-Stent Restenosis
9.3. Peripheral Artery Disease
9.3.1. Below Knee
9.3.2. Femoropopliteal
10. Drug Eluting Balloon Market, by End User
10.1. Introduction
10.2. Ambulatory Surgical Center
10.3. Clinic
10.4. Hospital
11. Drug Eluting Balloon Market, by Distribution Channel
11.1. Introduction
11.2. Direct
11.3. Distributor
12. Drug Eluting Balloon Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Drug Eluting Balloon Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Drug Eluting Balloon Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. B. Braun Melsungen AG
16.3. Balton Sp. z o. o.
16.4. Bayer AG
16.5. Becton, Dickinson and Company
16.6. Biosensors International Group, Ltd.
16.7. Biotronik SE & Co. KG
16.8. Boston Scientific Corporation
16.9. Cardionovum GmbH
16.10. Concept Medical
16.11. Cook Medical, Inc.
16.12. Eurocor Tech GmbH
16.13. Invamed
16.14. iVascular S.L.U.
16.15. Johnson & Johnson Services, Inc.
16.16. Koninklijke Philips N.V.
16.17. Laborie Medical Technologies, Inc.
16.18. Lepu Medical Technology
16.19. M.A. Med Alliance SA by Cordis Corporation
16.20. Medtronic PLC
16.21. SurModics, Inc.
16.22. Terumo Corporation
16.23. Wellinq
16.24. Zylox-Tonbridge Medical Technology Co., Ltd.
List of Figures
FIGURE 1. GLOBAL DRUG ELUTING BALLOON MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL DRUG ELUTING BALLOON MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL DRUG ELUTING BALLOON MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL DRUG ELUTING BALLOON MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL DRUG ELUTING BALLOON MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL DRUG ELUTING BALLOON MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL DRUG ELUTING BALLOON MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL PACLITAXEL-COATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL PACLITAXEL-COATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL PACLITAXEL-COATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL SIROLIMUS-COATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL SIROLIMUS-COATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL SIROLIMUS-COATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL CONVENTIONAL BALLOON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL CONVENTIONAL BALLOON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL CONVENTIONAL BALLOON MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL SPECIALTY BALLOON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL SPECIALTY BALLOON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL SPECIALTY BALLOON MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL CORONARY ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL DE NOVO LESION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL DE NOVO LESION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL DE NOVO LESION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL IN-STENT RESTENOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL IN-STENT RESTENOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL IN-STENT RESTENOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PERIPHERAL ARTERY DISEASE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PERIPHERAL ARTERY DISEASE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PERIPHERAL ARTERY DISEASE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL BELOW KNEE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL BELOW KNEE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL BELOW KNEE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL FEMOROPOPLITEAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL FEMOROPOPLITEAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL FEMOROPOPLITEAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL AMBULATORY SURGICAL CENTER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL AMBULATORY SURGICAL CENTER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL AMBULATORY SURGICAL CENTER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL CLINIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CLINIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CLINIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL DIRECT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL DIRECT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL DIRECT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL DISTRIBUTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL DISTRIBUTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL DISTRIBUTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 56. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 57. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 58. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 59. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 60. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 61. ASIA-PACIFIC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 62. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 64. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 65. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 66. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 67. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 68. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 69. NORTH AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 70. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 72. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 73. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 74. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 75. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 76. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 77. LATIN AMERICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 78. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 80. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 81. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 82. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 83. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 84. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 85. EUROPE DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 86. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 88. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 89. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 90. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 91. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 92. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 93. MIDDLE EAST DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 94. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 96. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 97. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 98. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 99. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 100. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. AFRICA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 105. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 106. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 107. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 108. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 109. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 110. ASEAN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 111. GCC DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 112. GCC DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 113. GCC DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 114. GCC DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 115. GCC DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 116. GCC DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 117. GCC DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. GCC DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 119. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 121. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 122. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 123. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 124. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 125. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 126. EUROPEAN UNION DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 127. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 128. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 129. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 130. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 131. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 132. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 133. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. BRICS DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 135. G7 DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 136. G7 DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 137. G7 DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 138. G7 DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 139. G7 DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 140. G7 DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 141. G7 DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. G7 DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 143. NATO DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 144. NATO DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 145. NATO DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 146. NATO DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 147. NATO DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 148. NATO DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 149. NATO DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 150. NATO DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 151. GLOBAL DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 152. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 153. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 154. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 155. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 156. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 157. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 158. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 159. UNITED STATES DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 160. CANADA DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 161. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 162. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 163. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 164. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 165. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 166. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. CANADA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 168. MEXICO DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 169. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 170. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 171. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 172. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 173. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 174. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 175. MEXICO DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 176. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 177. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 178. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 179. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 180. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 181. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 182. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 183. BRAZIL DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 184. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 185. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 186. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 187. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 188. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 189. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 190. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. UNITED KINGDOM DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 192. GERMANY DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 193. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 194. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 195. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 196. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 197. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 198. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 199. GERMANY DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 200. FRANCE DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 201. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 202. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 203. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 204. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 205. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 206. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. FRANCE DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 208. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 209. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 210. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 211. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 212. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 213. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 214. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. RUSSIA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 216. ITALY DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 217. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 218. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 219. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 220. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 221. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 222. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. ITALY DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 224. SPAIN DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 225. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 226. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 227. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 228. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 229. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 230. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. SPAIN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 232. CHINA DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 233. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 234. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 235. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 236. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 237. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 238. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. CHINA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. INDIA DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 241. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 242. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 243. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 244. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 245. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 246. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. INDIA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 248. JAPAN DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 249. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 250. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 251. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 252. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 253. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 254. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 255. JAPAN DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 256. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 257. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 258. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 259. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 260. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 261. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 262. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 263. AUSTRALIA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 264. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 265. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2017-2032 (USD MILLION)
TABLE 266. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 267. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 268. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 269. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2017-2032 (USD MILLION)
TABLE 270. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 271. SOUTH KOREA DRUG ELUTING BALLOON MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 272. GLOBAL DRUG ELUTING BALLOON MARKET SHARE, BY KEY PLAYER, 2025
TABLE 273. GLOBAL DRUG ELUTING BALLOON MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Balton Sp. z o. o.
  • Bayer AG
  • Becton, Dickinson and Company
  • Biosensors International Group, Ltd.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Concept Medical
  • Cook Medical, Inc.
  • Eurocor Tech GmbH
  • Invamed
  • iVascular S.L.U.
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips N.V.
  • Laborie Medical Technologies, Inc.
  • Lepu Medical Technology
  • M.A. Med Alliance SA by Cordis Corporation
  • Medtronic PLC
  • SurModics, Inc.
  • Terumo Corporation
  • Wellinq
  • Zylox-Tonbridge Medical Technology Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages186
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.48 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.66 Billion
Compound Annual Growth Rate16.2%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Implantable Drug Eluting Balloon Market - Global Forecast 2026-2032 - Product Image

Implantable Drug Eluting Balloon Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market - Global Forecast 2026-2032 - Product Image

Peripheral Scoring Drug-eluting Balloon Dilation Catheter Market - Global Forecast 2026-2032

  • Report
  • 189 Pages
  • Global
From
Drug Eluting Balloon Catheter Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Drug Eluting Balloon Catheter Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Drug Eluting Balloons Catheters Market Report 2026 - Product Image

Drug Eluting Balloons Catheters Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Drug Eluting Balloons (DEBs) - Global Strategic Business Report - Product Image

Drug Eluting Balloons (DEBs) - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From

About the Drug Eluting Balloon Market

The Drug Eluting Balloon (DEB) market is a subset of the medical device industry. DEBs are used to treat peripheral artery disease (PAD) and coronary artery disease (CAD). They are designed to deliver a drug directly to the site of the blockage, allowing for improved efficacy and reduced side effects. DEBs are typically composed of a balloon catheter with a drug-eluting coating. The drug is released when the balloon is inflated, allowing for targeted delivery of the drug to the affected area. DEBs have been shown to be effective in treating PAD and CAD, and are increasingly being used in clinical practice. They offer a minimally invasive alternative to traditional treatments such as stenting and bypass surgery. Some companies in the DEB market include Medtronic, Boston Scientific, Abbott, and B. Braun. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.